PD1/PDL1 ICIs
6 abstracts
Abstract
Next generation CD44v6-specific CAR-NK cells for the treatment of solid tumors.Org: Charité University Medicine Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany,
Abstract
Effect of aberrant N-glycosylation of PD-L1 on the potency of anti-PD-1 treatments.Org: Ben Gurion University of the Negev, Ben-Gurion University of the Negev,
Abstract
Neoadjuvant immunotherapy (neoIT) in melanoma: A prediction tool for pathological response and recurrence, and the role of adjuvant (Adj) therapy (Tx) to improve recurrence-free survival (RFS).Org: Sydney Medical School,
Abstract
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).Org: Melanoma Institute Australia, The University of Sydney, Sydney, Australia, Wollstonecraft, NSW, Australia, Sydney, NSW, Australia,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,
Abstract
Revealing a novel tumor immune escaping mechanism induced by macrophage-tumor fusion cells in HPV- cervical cancer through spatial SCRNA analysis.Org: Hong Kong University of Shenzhen Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, The University of Hong Kong-Shenzhen Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Southern University of Science and Technology,